The world’s first clinical trial of the new coronavirus inactivated vaccine of the Omicron variant strain completed inoculation in Hangzhou – Teller Report

IT House news on May 2, according to China Youth Daily, on May 1, the Omicoron variant (hereinafter referred to as the Austrian strain) new coronavirus inactivated vaccine developed by Sinopharm China Bio-Beijing Institute of Biological Products was clinically The first dose of vaccination was officially completed in Hangzhou City, Zhejiang Province. This is the world’s first inactivated vaccine against the new coronavirus that has entered clinical trials against the Ormicron variant.

The clinical study of the inactivated vaccine against the new coronavirus of the Austrian strain will adopt a non-randomized, open, and externally controlled research form..

Recently, the new crown pneumonia epidemic caused by Omicron variant has appeared in many places in China, which has the characteristics of strong infectivity, short incubation period, short passage time, and difficult prevention and control. Sino Biotech launched the vaccine development for the Ormicron variant on December 9, 2021, and obtained the clinical trial approval from the State Food and Drug Administration on April 26, 2022. After obtaining the clinical approval, the National Drug Clinical Trial Institute of Shulan (Hangzhou) Hospital immediately carried out the preparations before the start of the project, completed the review of the drug clinical trial ethics committee and obtained the ethics approval in the shortest time, and the clinical study was officially launched on May 1. .

The vaccine requires two doses and will evaluate the safety and immunogenicity of the Omicron variant vaccine in people 18 years of age and older who have not been vaccinated against the new coronavirus. After the clinical research data is approved, blank people who have not been vaccinated against the new crown vaccine can be directly vaccinated with the vaccine.